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While genetic lesions responsible for some Mendelian disorders can be rapidly 
discovered through massively parallel sequencing (MPS) of whole genomes or exomes, 
not all diseases readily yield to such efforts.  We describe the illustrative case of the 
simple Mendelian disorder medullary cystic kidney disease type 1 (MCKD1), mapped 
more than a decade ago to a 2-Mb region on chromosome 1.  Ultimately, only by cloning, 
capillary sequencing, and de novo assembly, we found that each of six MCKD1 families 
harbors an equivalent, but apparently independently arising, mutation in sequence 
dramatically underrepresented in MPS data:  the insertion of a single C in one copy (but 
a different copy in each family) of the repeat unit comprising the extremely long (~1.5-5 
kb), GC-rich (>80%), coding VNTR in the mucin 1 gene.  The results provide a cautionary 
tale about the challenges in identifying genes responsible for Mendelian, let alone more 
complex, disorders through MPS. 
 
Medullary cystic kidney disease (MCKD) type 1 (OMIM 174000) is a rare disorder characterized 
by autosomal dominant inheritance of tubulo-interstitial kidney disease1.  Affected individuals 
variably require dialysis or kidney transplantation in the third to seventh decade of life. Diagnosis 
of MCKD1 in patients is complicated by the unpredictable progression of kidney disease, the 
absence of other specific clinical manifestations, and the high frequency of mild kidney disease 
in the general population2.  Nonetheless, the disease has been compellingly and consistently 
mapped to a single autosomal locus at 1q213–7.  Attempts to identify the mutated gene(s), 
however, have not been successful4. 
 The advent of massively parallel sequencing (MPS) technologies has made exhaustive 
sequencing of genomic regions a viable approach to the identification of genes responsible for 
rare Mendelian diseases caused by high penetrance mutations8,9. Yet, there is also a growing 
recognition that using MPS to discover disease genes is not always straightforward.  Here, we 
report that MCKD1 is caused by an unusual class of mutations, recalcitrant to detection by MPS.  
The process of identifying the MCKD1 causal variation is of particular interest for human 
genetics, because it highlights important challenges in using current MPS for gene discovery.  
 Linkage analysis was performed on six likely MCKD1 pedigrees (Online Methods, 
Supplementary Fig. 1 and Supplementary Table 1), and in all families the phenotype showed 
perfect co-segregation with a single 2-Mb segment of chromosome 1 (Fig. 1).  We examined the 
genotype data for evidence of copy-number variation in the critical interval, but found only two 
common copy-number polymorphisms, neither of which segregated with disease.  Looking at 
the longest stretches of allelic identity within pairwise comparisons of the pedigrees’ phased 
risk-haplotypes, we also found no obvious ancestral haplotype shared by a significant fraction of 
the families (beyond the background LD in the general population). This result suggested that 
the families carried independently occurring mutations, consistent with the families’ diverse 
ancestries. 
 To search for mutations, we employed whole exome-, regional-capture- and whole 
genome sequencing (Online Methods).  We selected two affected individuals from each 
pedigree for sequencing, chosen, where possible, to share only a single haplotype (the risk 
haplotype) across the linkage region.  In protein-coding regions, we found only two rare (<1% in 
1000 Genomes Phase I data10), non-silent point variants (SNPs or small indels) shared by both 
of the affected individuals in any pedigree: each was in a different gene and each in a different 
pedigree.  This finding is consistent with the expected background rate for 75 genes in six 
independent risk chromosomes given the presence of 100-200 rare coding variants in a typical 
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genome10. In the context of perfect segregation of the phenotype, near-complete coverage of 
the coding bases in the linked region and the experience with other Mendelian diseases, we had 
expected to find a gene harboring rare coding variants in multiple families. To our dismay, we 
found no such evidence. 
 We next examined the non-coding regions, but found no regional clustering of 
segregating rare variants.  We searched for any large structural variation (hundreds of bases or 
larger) such as deletions, insertions, duplications and inversions. All variants identified in this 
manner either failed to segregate with disease or were found at appreciable levels in control 
populations.   
 At this point, we concluded that the causal mutation(s) in MCKD1 were either located in a 
subregion that was recalcitrant to sequencing or represented a novel mutational mechanism.  
We considered the possibility that MCKD1 might be due to expansions in a coding VNTR 
sequence, because recurrent mutations at coding VNTRs have been documented as the cause 
of many genomic disorders11 and because massively parallel sequencing data might not readily 
reveal such an expansion.  
 We used SERV (Sequence-based Estimation of minisatellite and microsatellite Repeat 
Variability)12 to identify highly variable tandem repeats (VNTRs) in or overlapping with coding 
regions of five genes contained within the disease-linked interval: KCNN3, EFNA3, ASH1L, 
MEF2D and MUC1.  Candidate VNTRs in the first four genes were found either to be non-
polymorphic or to show no notable expansion in affected individuals (relative to family members 
not sharing the risk haplotype and to CEPH family samples), based on direct assays of length 
by PCR. 
 The MUC1 VNTR was particularly difficult to assay: it consists of many (20-12513,14) 
copies of a large repeat unit (60 bases) with very high GC-content (>80%). We ultimately 
assayed the VNTR by Southern blot and confirmed results with long-range PCR (Online 
Methods).  In our patient samples, VNTR lengths were consistent with published descriptions 
and were not expanded on risk chromosomes, excluding VNTR length as pathogenic.  MUC1 
remained particularly interesting as the only gene in the critical region displaying transcripts with 
kidney-specific expression, based on RNASeq data from an adult control individual (unrelated to 
this study).  MUC1 encodes mucin 1, a transmembrane protein expressed on the apical surface 
of most epithelial cells, providing (amongst other functions) a protective barrier to prevent 
pathogens from accessing the cell surface.  The protein possesses a heavily glycosylated 
extracellular domain containing the VNTR and an SEA module with a cleavage site for release 
of the extracellular domain, which then binds noncovalently to the transmembrane domain17,19 
(Fig. 2a). 
 We considered the possibility that MCKD1 might be caused by point mutations within the 
MUC1 VNTR missed due to poor sequence coverage because (i) it was excluded from whole-
exome and regional-capture probes due to its low-complexity and extreme sequence 
composition (and also because it is rarely annotated as coding sequence) and (ii) it was 
dramatically underrepresented in quality-filtered data from the whole-genome sequence, likely 
due to its GC-richness and homopolymer content.  Because the human reference sequence 
appeared to significantly underrepresent this region (hg19 predicts a VNTR length far smaller 
than the published range or that observed in any of our samples, including controls), we 
undertook to clone and then reconstruct the VNTR alleles of several affected individuals and a 
CEPH trio; we subcloned, Sanger sequenced and performed de novo assembly for each (Online 
Methods and e.g. Fig. 2b-d). 
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 We found a number of point variants in the VNTR assemblies, but, with one exception, 
they either did not segregate with the risk haplotype or were present in the alleles of the CEPH 
trio and/or unaffected chromosomes.  However, we found one variant consistent with disease 
segregation: the insertion of a single C (relative to the coding strand of MUC1) within a stretch of 
seven C’s occurring at positions 53-59 in a single copy of the canonical 60-mer repeat (e.g. Fig. 
2e).  All six families carried such +C insertions, which appear to have arisen independently 
based on the different overall sizes of the VNTR, different local sequence contexts and different 
precise repeat units harboring the insertion (Supplementary Figs 2 and 3). 
The frameshift caused by the insertion predicts a mutant protein that contains many 
copies of a novel repeat sequence (obtained by shifted translation of the VNTR) but which lacks, 
owing to a novel stop codon shortly beyond the VNTR terminus, the downstream SEA self-
cleavage module and both transmembrane and intracellular domains characteristic of the 
normal MUC1 precursor protein (Fig. 2a). 
 Because discovery of the +C insertion required considerable labor and time, we sought to 
develop a simple and robust genotyping assay to enable larger population screening.  We 
designed a probe-extension assay (Online Methods and Fig. 3a) capable of distinguishing 
reference and mutant MUC1 VNTR repeat units, making use of MwoI (which selectively cleaves 
the reference sequence) to increase the stoichiometric ratio of mutant:reference repeat units.	  
 We typed all samples collected from the six MCKD1 families used for linkage analysis, 
including 62 phenotypically affected and 79 unaffected relatives (Fig. 3b-c), and over 500 
control individuals from CEU, Japanese, Chinese, Yoruba and Tuscan HapMap3 populations 
(Fig. 3d). The genotyping assay was perfectly concordant with sequencing results, and full 
genotyping of all family members showed that the insertion segregated perfectly with each 
family’s risk haplotype and yet was not seen in any of the 500 HapMap samples. 
 Overall, the genotyping results provide strong evidence that the +C insertions are the 
high-penetrance genetic lesion that leads to development of MCKD1. As a statistical association, 
the significance of this observation can only be approximated, but it is clearly far less than the 
reciprocal of the number of bases in the genome (+C seen on 6/6 risk chromosomes vs. 0/1000 
HapMap chromosomes). Furthermore, this observation is robust to population structure 
considerations since the mutations have arisen independently. 
 To explore the broader impact of MUC1 mutations, we genotyped affected and 
unaffected individuals from 21 additional small MCKD families screened to be negative for 
known MCKD mutations (Supplementary Table 1), only one family of which had existing 
linkage information implicating 1q2115.  In 13 of 21 families we found the presence of a +C 
insertion consistent with being a fully penetrant cause of disease, indicating a substantial role for 
MUC1 in MCKD1-like phenotypes. 
 Using antibodies raised against a peptide synthesized based upon the predicted mutant 
VNTR sequence, we found specific intracellular staining in epithelial cells of Henle´s loop, distal 
tubule and collecting duct of MCKD1 patients (Fig. 4a), which was absent in control kidney (Fig. 
4b).  Co-staining of patient and control tissue additionally with antibodies against normal MUC1 
demonstrated the specificity of the MUC1-fs (our name for the predicted mutant protein) 
antibodies for the mutant protein, with diffuse and/or fine granular intracellular localization of the 
MUC1-fs protein in patient kidney (Fig. 4c), and also patchy co-localization of MUC1-fs and 
normal MUC1 signals on the apical membrane of collecting duct epithelial cells (Fig. 4c and 4d). 
Detailed image analysis of patient tissue (Fig. 4d) compared to control tissue (Fig. 4e) detected 
no intracellular co-localization of MUC1-fs and normal MUC1 proteins in patient tissue, but 
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revealed puncti of colocalization in distinct plasmalemmal subdomains.  Antibody to MUC1-fs 
did not stain normal kidney tissue. 
 This study highlights the fact that current MPS technology may not suffice to reveal 
disease mutations, even when linkage analysis conclusively pinpoints a critical region of a few 
megabases.  Even if the insC event were not dramatically underrepresented in the quality-
filtered MPS data and even if the reference genome assembly had been accurate in this region, 
it still would have been difficult to detect this particular insertion event using typical alignment 
and variation-detection tools due to (1) the underlying variability of VNTR size within and across 
individuals, (2) the inability to uniquely place reads within the VNTR, given current MPS read 
lengths, and (3) the fact that the mutant:reference allelic balance is skewed far from the 
expected 1:1 of a typical heterozygous variant. 
 The precise nature of the MCKD1 mutations is notable. Curiously, each independently-
arising event is essentially the identical single-base insertion at the same position within one of 
the repeat units of the VNTR. Yet, insertions at many locations or other events (such as single-
base deletions) would also result in out-of-frame translation of MUC1 and/or novel stop codons. 
Possible explanations for the consistently observed mutation include:  (1) this insertion event is 
strongly favored due to mutational mechanism, (2) other events (eg. delC) are selected against, 
(3) other events (eg. delC) are benign and not associated with MCKD1, and (4) other MUC1 
mutations exist but are undersampled here. 
 The identified mutation and the associated genotyping assay provide a screening tool for 
younger members of families in which MCKD1 has been previously diagnosed, as well as a 
diagnostic tool for sporadic cases.  They also alleviate the challenge for living relative kidney 
donation, as potential donor family members have not known their status as unaffected or (yet-
to-be) affected.  Much work, however, remains to be done to elucidate the specific mechanism 
of pathogenesis of the MUC1 mutant protein. We note that knock-out studies indicate that the 
MUC1 gene is not essential in mice16 and support a possible dominant-negative and/or gain-of-
function mode of action for the human MUC1 mutation.  Together with the dominant and late-
onset nature of the disease, this raises the possibility of preventative or therapeutic approaches 
based on treatments that decrease expression of the MUC1 gene or splice out its single VNTR-
encoding exon. 
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FIGURE LEGENDS 
 
Figure 1.  Linkage of six MCKD1 families to chromosome 1.  LOD curve shows the 
combined linkage-score of six MCKD1 pedigrees across 12 Mb of chromosome 1, with the peak 
score well above the threshold of 3.6 for genome-wide significance17.  Red X's mark the 
locations of opposite-allele homozygous genotype calls between affected members within each 
pedigree and highlight regions where affected individuals de facto share no alleles IBD, thereby 
delineating genomic segments unlikely to harbor causal variation.  The shaded region 
(hg19:chr1:154,370,020–156,439,000) was considered most likely to contain any causal 
mutations, bounded on each side by recombination breakpoints in two different pedigrees. 
 
Figure 2.  Discovery of +C insertion within MUC1 coding VNTR.  (a) The major domains of 
the full-length MUC1 precursor protein are shown:  N-terminal signal sequence, VNTR, SEA 
module (where cleavage occurs), transmembrane domain, and C-terminal cytoplasmic domain.  
Based on fully and unambiguously assembled VNTR alleles, the frameshift caused by insertion 
of a C in the coding strand (as described in the main text) is expected to introduce a novel stop 
codon shortly beyond the VNTR domain.  (b and c) Where possible, knowledge of segregating 
phased SNP-marker haplotypes was used to select for de novo VNTR sequencing and 
assembly of those individuals sharing only a single haplotype across the region, as this aided 
identification of the VNTR allele segregating with the shared risk haplotype.  (d and e)  
Independent de novo assembly of the shared VNTR allele in two individuals from family 4 shows 
exactly identical complete sequence, with the seventh 60-base unit (red X) out of 44 containing 
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a +C insertion event.  The assembly is oriented relative to the coding strand of MUC1 and 
covers bases chr1:155,160,963-155,162,030 (hg19).  Each unique 60-base repeat segment is 
represented by a different letter or number (Supplementary Fig. 2). (e) Translational impact of 
+C frameshift. 
 
Figure 3. Detection of MUC1 +C insertion by probe-extension (PE) assay.  (a)  Exemplar 
electropherograms for the MUC1-VNTR +C-insertion PE assay (Online Methods) performed on 
homozygous reference-allele and heterozygote samples.  (b) Allele-intensity scatterplot for large 
linkage family 2.  X-axis values correspond to the detected intensity at the mass of the +C PE 
product, while Y-axis values reflect that of the reference repeat-unit extension product.  Datum 
coloring reflects MCKD1 diagnosis:  blue = unaffected (or HapMap samples), red = affected, 
white = unknown.  Individuals known to carry the linkage-analysis risk haplotype are 
represented by “+”, while other family members are depicted as dots.  (c)  Allele-intensity 
scatterplot for all MCKD1 linkage families.  Samples having log-transformed intensities below 
0.25 for both alleles were excluded as failed assays.  WGA and low DNA-concentration samples 
were also excluded for underperforming.  (d) Allele-intensity scatterplot for HapMap samples 
together with selected positive controls (MCKD1 individuals known to carry the insertion). 
 
Figure 4. Immunohistochemical and immunofluorescence studies of MUC1-fs protein.  In 
MCKD1 patients, MUC1-fs is expressed and present in renal epithelial cells of Henle´s loop, 
distal convoluted tubule, and collecting duct. (a) Strong intracellular staining of MUC1-fs protein 
in MCKD1 patient, and (b) absence of the specific staining in control; TALH - thick ascending 
limb of Henle´s loop; CD – collecting duct; PT – proximal tubule. (c) Immunofluorescence 
analysis showing diffuse and/or fine granular intracellular and membrane staining of MUC1-fs 
protein, and its partial colocalization with normal MUC1 in collecting duct of an MCKD1 patient. 
MUC1-fs staining is absent in control, and colocalization with normal MUC1 is therefore not 
detected. The values of fluorescent signal overlaps are transformed to a pseudo-color scale 
shown at right bottom in the corresponding lookup table. (d) Immunofluorescence analysis 
showing different intracellular localizations and partial sub-membrane colocalization of MUC1-fs 
and normal MUC1 proteins in collecting duct of MCKD1 patient. Note specific staining of both 
forms in distinct membrane microdomains. (e) Absence of MUC1-fs staining and characteristic 
membrane localization of normal MUC1 in control.  
 
ONLINE METHODS 
 
Family collection and criteria for diagnosis of affected status.  The six analyzed families 
with autosomal dominant tubulointerstitial kidney disease were among a larger group referred 
for evaluation.  Each showed a clinical phenotype highly suggestive of MCKD1 and lacked 
UMOD or REN mutations.   All had previously demonstrated evidence of linkage to chromosome 
1.  Written informed consent was obtained from all participants and the study was approved by 
the Wake Forest School of Medicine Institutional Review Board.  Medical records were reviewed 
and peripheral venous blood samples were obtained for DNA isolation and laboratory 
determinations.  Full diagnostic methods and clinical summaries are described in 
Supplementary Note. 
 
Linkage and CNV analysis.  Family members were genotyped on the Affymetrix 6.0 platform.  
Whole Affymetrix arrays with genotype call rates < 88% were excluded from analysis, as were 
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samples which yielded low OD measurements (indicating poor sample performance during 
laboratory steps).  Further, markers were excluded for which probe sequences showed excess 
genomic homology or potential for significant G-quartet formation (those probe sequences for 
which either allele contained at least three consecutive G’s). 
 Particularly large pedigrees (>24 bit complexity) were divided into branches where 
required by computational constraints.  LD-independent marker maps were separately created 
for each pedigree/branch, choosing single, well-typed, informative markers from LD-defined bins 
of SNPs based on phased, population-specific HapMap data (hapmap.org, release 22).  
Markers which showed no-call rates > 10% or any Mendelian inheritance errors within a 
pedigree/branch were excluded from specific pedigree/branch analyses.  Additionally, markers 
were required to be spaced at least 0.1 cM apart according to published sex-averaged 
recombination positions (affymetrix.com). 
 All expected intra-pedigree relationships were confirmed from pairwise IBD estimates 
using PLINK software18 and similarly derived marker sets; however, markers for PLINK were 
selected agnostic to their being polymorphic within a pedigree/branch so as not to skew IBD 
calculations.  Merlin software19 was used to remove any likely genotyping errors which did not 
violate Mendelian inheritance rules, and then to perform parametric linkage under a rare, 
autosomal-dominant model using population-specific allele frequencies (affymetrix.com).   
 Linkage mapping was performed using the Merlin package under a rare autosomal-
dominant model.  Scores were combined across pedigrees/branches by summing LOD values, 
linearly interpolating scores between marker locations as required. The consistency of the 
alleles carried on the segregating risk haplotype was confirmed across pedigree branches. 
 The boundaries of the linked region were refined by searching all well-typed markers -- 
including many that were dropped solely to eliminate markers in LD from the linkage calculations 
-- for instances where affected members within the same pedigree shared no alleles IBD (by 
virtue of being homozygous for opposite alleles – for example, one having genotype AA and 
another CC). Such markers necessarily lie outside the critical linkage interval. 
 Affymetrix 6.0 intensity data were used by Birdsuite software20 to analyze copy-number 
variation. 
 
Large-scale sequencing.  Because the critical region contains more than 170 separate 
transcript annotations comprising over 75 RefSeq genes, amplicon-based resequencing of genic 
regions was initially not considered.  Of the 12 sequenced individuals, whole-genome 
sequencing was performed on 11 of these individuals (~25-fold coverage on average), whole-
exome sequencing on 11 individuals (~180-fold coding-sequence coverage on average) and 
regional-capture sequencing on 5 individuals (~220-fold coverage on average).  Sequence 
processing is described in Supplementary Note. For all but three of the RefSeq genes, at least 
99% of the coding bases were covered at ≥10-fold in each pedigree.  Further, 98% of non-
coding bases were covered at ≥10-fold in each pedigree. 
 As candidates for being pathogenic MCKD1 mutations, we considered any non-reference 
allele present in both affected individuals of any pedigree and with a population frequency ≤1%10. 
Non-coding regions were analyzed similarly. 
 To discover potential structural variation at the chromosome-1 locus, we ran Genome 
STRiP21 on the sequenced individuals and on a control population of 32 Finnish genomes 
sequenced at low coverage by the 1000 Genomes Project10 (Supplementary Note). 
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MUC1-VNTR Southern blot analysis.  Genomic DNA (5-8 µg) was digested with 100 u HinfI 
(NEB). Digests were run on a 0.8% agarose gel, transferred to a BrightStar Plus Nylon 
membrane (Ambion) and hybridized overnight at 65˚C to a quadruply biotinylated synthetic 
100mer oligonucleotide probe PS1 (Supplementary Table 3) (IDT) present at 2 ng/ml in 
SuperHyb hybridization solution (Ambion) supplemented with 100 µg/ml sonicated salmon 
sperm DNA (Stratagene). After a final high-stringency wash at 65˚C in 0.2x SSC and 0.1% SDS, 
membrane-bound biotin was detected by a BrightStar BioDetect kit (Ambion). 
 
MUC1-VNTR long-range PCR.  The long-range PCR protocol was adapted from Fowler et al.14. 
Briefly, 7-µL PCR reactions contained 15 or 30 ng genomic DNA, 1.75 pmol of PS2 and PS3 
primers (Supplementary Table 3), 5% DMSO, 625 µM of each dNTP, 1x reaction buffer with 3 
mM MgCl2, and 0.25 u DyNAzyme EXT DNA polymerase (Finnzymes). Thermocycling on 
GeneAmp 9700 instruments (ABI) was as follows: initial denaturation (90 s at 96˚C); 22 or 27 
cycles (40 s at 96˚C, 30 s at 65˚C, 6 min at 68˚C) and final extension (10 min at 68˚C). 
 
MUC1-VNTR sequencing and assembly.  For selected individuals, we cloned gel-purified 
long-range-PCR products containing the full-length VNTR.  Allele sizes derived from Southern 
blots and long-range PCR, together with known haplotype sharing between individuals in the 
same pedigree, in most cases permitted the identification of which MUC1 VNTR allele was part 
of the segregating risk haplotype (e.g. Fig. 2b and c).  In a few cases, the sizes of the risk and 
non-risk VNTR allele were nearly the same, precluding physical separation of the two alleles 
prior to molecular cloning. Using transposon hopping and capillary sequencing, we then 
sequenced clones from each allele (Supplementary Note).   
 Because the region is exceptionally repetitive and because the read data contain both 
PCR errors and sequencing errors (exacerbated by the extreme GC content of the repeat), we 
developed a special assembly algorithm that could distinguish bona fide genomic differences 
from errors (Supplementary Note). Given the repetitive sequence content, not all assemblies 
were complete or unambiguous.  Instead, some assembly frameworks suggested multiple 
possible resolutions across areas of uncertainty, forming full networks of possible solutions for a 
particular allele. 
 Supplementary Table 2 summarizes the key properties of the assemblies (example 
shown in Figure 2d), and Supplementary Figures 3 and 4 provide the sequence for those 
unique alleles (three risk and eight non-risk) where the assembly was fully or almost fully 
resolved. Supplementary Figure 5 illustrates the notation of graph assembly in a scenario 
where an allele could not be fully and unambiguously reconciled.  We assembled each allele 
separately and independently.  In all situations where two alleles were expected to be identical 
by haplotype sharing and where the assemblies were fully resolved, the assemblies were 
indeed identical – thus increasing our confidence that the assemblies were correct.  
 
Genotyping of MUC1 +C insertion event.  Genomic DNA was first over-digested using 
restriction endonuclease MwoI which selectively cleaves the reference repeat-unit sequence 
(GCCCCCCCAGC), while leaving intact repeat units containing the +C insertion 
(GCCCCCCC*C*AGC). Tailed primers nested within the 60-bp repeat were then used to PCR 
amplify the remaining intact VNTR fragments, thus enriching for insertion-containing fragments 
over reference-sequence background. PCR products were then re-digested with MwoI for a 
second round of enrichment. A 20-bp probe was then designed just upstream of the insertion 
site, and probe extension was performed using a high fidelity DNA polymerase and a nucleotide 
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termination mix containing dATP, ddCTP and ddGTP. Following probe extension, reaction 
products were separated and sized by MALDI-TOF mass-spectrometry using the Sequenom 
MassArray platform.  Spectra were then assessed for the presence of peaks corresponding to 
the mutant repeat-unit extension-product (at 5,904.83 daltons) and the reference repeat-unit 
extension-product (at 6258.06 daltons). 
 Specifically, 100 µg of genomic DNA was digested in a 25-µL reaction volume for 16 
hours using 5 units of MwoI restriction endonuclease (New England Biolabs) with supplemental 
additions of 5 units of enzyme at hours 3 and 15. Digestion reactions were then cleaned using 
50 µL AmPure beads according to manufacturers protocol (Agencourt, Beverly, MA), and 
digested DNA was eluted in 25 µL of nuclease-free water. Remaining intact VNTR fragments 
were PCR-amplified using 1X HotStart buffer, 1.0 mM MgCl2 (to supplement MgCl2 already in 
buffers), 0.8 mM dNTPs, 0.8 units of HotStart Taq Plus (Qiagen) and 0.2 µM forward and 
reverse primers PS6 and PS7 (Supplementary Table 3) in a 25-µL reaction volume. PCR 
cycling conditions were: one hold at 95°C for 5 min; 45 cycles of 94°C for 30 sec, 67°C for 30 
sec, 72°C for 1 min; followed by one hold at 72°C for 10 min. PCR reactions were cleaned using 
50 µL AmPure beads, and amplicons were eluted in 25 µL nuclease-free water. A second round 
of MwoI digestion was performed again for 16 hours with 5 units of enzyme added at hours 0, 3 
and 15. Digestion reactions were cleaned using 50 µL AmPure beads and product was eluted in 
6.2 µL of nuclease-free water.  
 Using 5.2 µL of the digested eluate as template, probe extension was performed using 
1X HotStart buffer, 0.6 mM MgCl2 (to supplement MgCl2 already in buffers), 1.7 µL SAP buffer 
(Sequenom, San Diego, CA), 0.2 mM each of nucleotides ddGTP, ddCTP and dATP; 0.7 units 
of Thermo Sequenase DNA polymerase (Amersham) and 0.6 µM of extension probe PS8 
(Supplementary Table 3) in a 10-µL reaction volume. Probe extension was performed on a 
384-well ABI GeneAMP 9700 and cycling conditions were: one hold at 94°C for 2 min 55 cycles 
of 94°C for 5 sec, 52°C for 5 sec, 72°C for 5 sec; followed by one hold at 72°C for 7 min. 
Reactions were then de-salted by addition of a cation-exchange resin, and ~7 nL of purified 
extension reaction was spotted onto a SpectroChip (Sequenom) containing matrix 3-
hydroxypicoloinic acid. Arrayed reactions were then analyzed by matrix-assisted laser 
desorbtion/ionization-time of flight (MALDI-TOF) on a Compact mass spectrometer 
(Sequenom/Bruker). 
 Assay results were clear enough to assign genotypes based on simple inspection of X-
Y scatterplots depicting log-transformed reference- and mutant-repeat-unit intensities 
(log10(1.0+peak height)).  Samples showing log-transformed intensities < .25 for both alleles 
were considered failed assays.  Similarly, results from whole-genome-amplification samples or 
samples with low DNA concentrations were typically considered unreliable and discarded. 
 
Antibody generation and kidney immunostaining.  Immunodetection of MUC1-fs was 
performed with custom-prepared rabbit antibodies (PA4 302) raised against the peptide 
SPRCHLGPGHQAGPGLHRPP, representing the predicted mutant VNTR unit (Open 
Biosystems, Huntsville, AL; diluted 1:1000 in 5% BSA in PBS). The normal MUC1 protein was 
detected with monoclonal mouse anti-human Epithelial Membrane Antigen (EMA) mouse 
monoclonal antibody (DAKO, Glostrup, Denmark; diluted 1:400 in 5% BSA in PBS). Detection of 
bound primary antibody was achieved using either Dako EnVision + TM Peroxidase Rabbit Kit 
(Dako) or System-HRP labeled Polymer Anti-mouse (DAKO), for rabbit or mouse antibodies, 
respectively, with 3,3´-diaminobenzidine as substrate. 
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 Paraformaldehyde-fixed human kidney biopsies were analysed. The specificity of antigen 
detection was always ascertained by omission of the primary antibody-binding step. 
 For immunofluorescence analysis, PA4 302 antibody was diluted 1:200 in 5% BSA in 
PBS and EMA antibody was diluted 1:10 in 5% BSA in PBS. Fluorescence detection used 
species-specific secondary antibodies.  Alexa Fluor® 488 goat-anti rabbit IgG and Alexa Fluor® 
568 goat-anti mouse IgG (Molecular Probes, Invitrogen, Paisley, UK). Nuclei were stained with 
4',6-diamidino-2-phenylindole (DAPI). Prepared slides were mounted in Immu-Mount 
fluorescence mounting medium (Shandon Lipshaw, Pittsburgh, PA) and analyzed by confocal 
microscopy. 
 XYZ images sampled according to Nyquist criterion were acquired using a TE2000E C1si 
laser scanning confocal microscope, Nikon PlanApo objective (40x, N.A.1.30), 488 nm and 543 
nm laser lines and 515 +/-15 nm and 590 +/-15 nm band pass filters. Images were deconvolved 
using the classic maximum likelihood restoration algorithm in Huygens Professional Software 
(SVI, Hilversum, The Netherlands).	  Colocalization maps employing single pixel overlap 
coefficient values ranging from 0-1 were created using Huygens Professional Software. The 
resulting overlap coefficient values are presented as pseudo-color (scale is shown in 
corresponding figure lookup tables). 
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Mutations causing medullary cystic kidney disease type 1 (MCKD1) lie in a 
large VNTR in MUC1 missed by massively parallel sequencing 
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Diagnostic methods and clinical summaries 
 
Family collection and phenotyping 
 
As previously described in families with MCKD1, these families shared the 
following characteristics: absent or low grade proteinuria with bland urinary 
sediments; slowly progressive kidney dysfunction; absence of causative findings 
on renal ultrasound; and absence of other associated signs or symptoms of 
systemic disease.  Hypertension tended to occur only after the onset of chronic 
kidney failure.  
 
Given these clinical characteristics, the only quantifiable relevant phenotype for 
analysis was estimated glomerular filtration rate (GFR).  Often serum creatinine 
is used to measure kidney function, as serum creatinine levels are reciprocally 
related to glomerular filtration rate.  However, serum creatinine levels are also 
affected by other factors, including protein intake and muscle mass, making it an 
inaccurate renal function marker in people with preservation of 70%-100% of 
normal kidney function.  The MDRD formula estimates kidney function based on 
race, gender, age, and serum creatinine.  Unfortunately, this formula is also 
inaccurate for patients with 70%-100% of normal kidney function.  To further 
complicate matters, kidney function normally decreases with age, with some 
individuals experiencing significant loss of function – this is especially the case in 
African Americans and Native Americans.  
 
Therefore, we considered the age and GFR in arriving at clinical diagnoses.  We 
did not include in the analysis individuals less than 18 years of age, as even 
affected individuals under 18 could have a normal GFR.  Individuals with 
significantly abnormal kidney function for their age were considered affected.  
Individuals were considered unaffected if kidney function was normal or if they 
were older and still had relatively preserved kidney function.  In most of the 
families, affected individuals initiated renal replacement therapy (started dialysis) 
between 40 and 60 years of age. 
 
Accordingly, individuals were considered affected if they required renal 
replacement therapy, had biopsy-proven interstitial kidney disease, or had an 
estimated GFR > 2 standard deviations below the mean, adjusted for age and 
race.  Individuals were considered to be unaffected if they were greater than 25 
years of age and their estimated GFR was considered significantly higher than 
expected for affected family members.  Approximately one-third of family 
members were excluded from initial genetic analysis due to indeterminate renal 
phenotypes.   
 
Clinical summaries 
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All six families were linked to Chromosome 1 and had very consistent and similar 
presentations (Supplementary Table 1).  For all affected individuals in the 
families, urinalysis results revealed minimal proteinuria and no hematuria.  
Pathology from kidney biopsies consistently revealed tubulo-interstitial fibrosis 
with no or minimal inflammatory infiltrate.  Renal ultrasounds occasionally 
revealed some cortical cysts, but there were no medullary cysts identified.  In 
most families, the disease was present in several generations and was always 
consistent with autosomal dominant inheritance.  The age of onset of end-stage 
kidney disease varied somewhat between families.  One family had associated 
bipolar disease, which was not present in any other families. 
 
Family 1 includes 4 generations with autosomal dominant inheritance of 
interstitial kidney disease.  Ages of end-stage kidney disease ranged from 29 to 
69.  Urinalyses from three affected family members revealed no blood or protein, 
and historically, there were no family members in whom hematuria or proteinuria 
was noted.   A kidney biopsy performed on one family member and revealed 
focal interstitial fibrosis with tubular atrophy affecting approximately 30 to 40% of 
the tubule-interstitial areas. 
 
Family 2 includes 4 generations of affected individuals with the autosomal 
dominant inheritance of progressive interstitial kidney disease. Kidney biopsy 
was performed on one individual who was being considered as a potential kidney 
donor and had normal kidney function (serum creatinine 0.9 mg/dl).  Results of 
the biopsy showed patchy, mild interstitial fibrosis with associated mild tubular 
atrophy and a variable mixed inflammatory infiltrate including occasional 
eosinophils.   Four renal ultrasounds in different affected family members 
revealed three with cortical cysts and two with small kidneys bilaterally.  
Urinalyses in affected individuals revealed no protein or blood.  Age of kidney 
failure requiring dialysis ranged from 25 to 67 years, with some family members 
in their 60’s with stage III kidney disease. 
 
Family 3 has been extensively described1.  Affected family members span 5 
generations, with ages of onset of kidney failure ranging from 36 to 67 years.  
Characteristics of disease have included a steady, progressive decline in kidney 
function.  Urinary examination in affected individuals revealed the absence of 
hematuria or proteinuria.  Kidney biopsy results from four individuals1 revealed 
tubular atrophy and interstitial fibrosis without a glomerular lesion.  In the study of 
Kiser, renal ultrasound in 9 individuals revealed small bilateral cysts at the 
corticomedullary junction in one patient, 3 patients with acquired cystic disease, 3 
with increased echogenicity, and 2 normal ultrasounds.  In our analysis of this 
family, there were five renal ultrasounds, in which one individual had small 
cortical cysts, and three of the five ultrasounds revealed small, echogenic 
kidneys.  None of the patients in the previous report had glomerulonephritis on 
biopsy or proteinuria or symptoms of other kidney diseases.  In our evaluation, 
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there was one patient with proteinuria and diabetes who appeared to have 
diabetic nephropathy; mutational analysis in this patient was negative for the 
MUC1 gene mutation, and in linkage studies, this patient had been labeled as 
having an uncertain diagnosis. 
 
Family 4 was identified from referral of a 44-year-old female with chronic kidney 
disease whose urinalysis revealed no blood or protein.   A kidney biopsy revealed 
widespread distention of tubules and chronic active interstitial nephritis with small 
microcystic changes to the tubules.  The patient’s sister underwent a kidney 
biopsy at age 27 years which showed moderate patchy interstitial fibrosis with 
tubular atrophy.  Inheritance of kidney disease was documented as autosomal 
dominant over 5 generations, with family members starting dialysis between the 
ages of 45 and 79 years. 
 
Family 5 suffers from the autosomal dominant inheritance of both interstitial 
kidney disease and bipolar disease, both having been linked to chromosome 12.  
There were no other associated physical findings in this family, and no other 
families studied suffered from bipolar disease or other psychiatric disorders.  Age 
of onset of kidney failure was younger than in other families, with the need for 
renal replacement therapy occurring at ages 22 to 33 over three generations.  
There was no kidney biopsy material available.  Urine studies in this family were 
negative for blood and protein.  All clinical findings were very consistent with 
MCKD1. 
 
Family 6 is of European descent from the mid-West of the United States has 
previously been described (Kindred B in the investigation of Lindeman et al.3).   
The autosomal dominant inheritance of interstitial kidney disease was noted over 
5 generations.   In one individual, at autopsy results revealed marked atrophy of 
the tubules and marked interstitial fibrosis; no cysts were present.  No glomerular 
changes were noted.  Age of onset of end-stage kidney faiure ranged from 27 to 
44 years.  Renal ultrasound in one individual revealed normal sized kidneys and 
occasional cysts.  Urinalysis results in family members did not reveal blood or 
protein. 
 
Supplementary Table 1 also presents data on families that were tested for the 
C insertion in the VNTR of the MUC1 gene.  Except for Family 64, which had 
previously been linked to the area of interest on Chromosome 1,  linkage studies 
had not been done in these families.    All families demonstrated findings 
consistent with MCKD1:  autosomal dominant inheritance was present; urinalysis 
in affected individuals were bland without hematuria and with minimal proteinuria; 
renal biopsies revealed interstitial fibrosis, and there were no associated clinical 
abnormalities of other organ systems.  In two families, kidney biopsy material 
was stained with the antibody to the mutant MUC1 protein, with results similar to 
those documented in the figure in the main manuscript.   
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Large-scale regional sequencing 
 
Whole-genome and whole-exome sequencing 
 
Whole-genome and whole-exome libraries were sequenced on either Illumina 
HiSeq 2000 or Illumina GAIIX with the use of 101-bp paired-end reads for whole-
genome sequencing and 76-bp paired-end reads for whole-exome sequencing. 
 
For a subset of samples, starting with 3 µg of genomic DNA, library construction 
was performed as described by Fisher et al5. Another subset of samples, 
however, was prepared using the Fisher et al. protocol with some slight 
modifications:  initial genomic DNA input into shearing was reduced from 3 µg to 
100 ng in 50 µL of solution. 
 
Exomes were captured using the Agilent SureSelect v2.  For a subset of whole-
genome samples, size selection was performed using gel electrophoresis, with a 
target insert size of either 340 bp or 370 bp +/- 10%. Multiple gel cuts were taken 
for libraries that required high sequencing coverage.  For another subset of 
whole-genome samples, size selection was performed using Sage’s Pippin Prep. 
 
Following sample preparation, libraries were quantified using quantitative PCR 
(kit purchased from KAPA biosystems) with probes specific to the ends of the 
adapters. This assay was automated using Agilent’s Bravo liquid handling 
platform. Based on qPCR quantification, libraries were normalized to 2 nM and 
then denatured using 0.1 N NaOH using Perkin-Elmer’s MultiProbe liquid 
handling platform.  
 
Cluster amplification of denatured templates was performed according to the 
manufacturer’s protocol (Illumina) using either Genome Analyzer v3, Genome 
Analyzer v4, HiSeq 2000 v2, or HiSeq v3 cluster chemistry and flowcells. For a 
subset of samples, after cluster amplification, SYBR Green dye was added to all 
flowcell lanes, and a portion of each lane visualized using a light microscope, in 
order to confirm target cluster density. Flowcells were sequenced either on 
Genome Analyzer IIX using v3 or v4 Sequencing-by-Synthesis Kits, then 
analyzed using RTA v1.7.48; or on HiSeq 2000 using HiSeq 2000 v2 or v3 
Sequencing-by-Synthesis Kits, then analyzed using RTA v1.10.15. or RTA 
v.1.12.4.2. 
 
Custom capture-array 
 
A custom sequence-capture microarray was designed to perform target 
enrichment of chromosome 1 152-156 Mb (hg18), including the critical MCKD1-
linked region.  The four megabase region was tiled with probes using Nimblegen 
in-house repeat masking algorithm6.  Each array contains 385,000 probes tiled 
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with ~5 bp overlap, excluding the repetitive sequence. The probe set covered 
70% of the 4-Mb target region, or 85% if 100 bp offset around probes is used. 
 
For each sample we fragmented 5 µg of genomic DNA, using a water bath 
sonicator (Bioruptor, Diagenode) on high power. The sonication program was 
cyclical, 30 seconds on and 30 seconds off for a total of 15 minutes to obtain 
fragments of 200 to 800 bp. The size of the fragments was evaluated on 
DNA1000 chips (Agilent 2100 Bioanalyzer, Agilent).  Library preparation was 
performed using the Illumina Paired end kit according to the manufacturer’s 
protocol. In short: DNA fragments were blunt ended with T4 and Klenow 
polymerases and T4 polynucleotide kinase with 10 mM dNTP.  A 3’ adenosine 
overhang was added using Klenow exo fragment and 1 mM dATP followed by 
ligation of Illumina sequencing adapters with Quick ligase. The agarose gel 
electrophoresis size-selection step was omitted. Ligated fragments were enriched 
using 11-15 cycles of linker mediated (LM) PCR using a high-fidelity polymerase 
(Phusion, Finnzymes). 1 µg of cleaned PCR product was hybridized on the 
Roche Nimblegen Sequence Capture array following the manufacturer’s protocol. 
After 3 days of hybridization, slides were washed and the enriched DNA was 
eluted. Eluted DNA was amplified with 14-18 cycles of LM-PCR, cleaned with 
QIAquick PCR purification kit (Qiagen) and quantified. Sequence capture 
efficiency was verified using real-time PCR amplification of three primer sets 
within the target region and three primer sets outside of the target region. 
Amplification of primer sets inside and outside the target region was compared 
using both sequence capture-enriched DNA and pre-capture DNA. An eight-to-
ten fold difference in rt-PCR amplification was deemed to be successful 
enrichment. 
 
Sequence analysis 
 
Sequence data was processed with Picard (http://picard.sourceforge.net/)7 and 
BWA8 for mapping reads. SNPs and small indels were called using GATK, which 
utilizes base quality-score recalibration and local realignment at known indels7,9. 
The analyzed variable sites were restricted to those that pass GATK standard 
filters to eliminate events with strand-bias, low quality for the depth of sequencing 
achieved, homopolymer runs, and SNPs near indels.   
 
We ran Genome STRiP both with the default parameters and also with relaxed 
parameter settings to attempt to increase sensitivity. In normal use, Genome 
STRiP looks only for signatures of large deletions indicated by unusual spacing 
or orientation of read pairs. For this application, we additionally enabled Genome 
STRiP to perform read pair clustering across all possible read pair orientations to 
generate a set of 2,208 loci that might potentially contain some form of structural 
variation. 
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We reviewed the evidence for each potential SV locus, looking for evidence of 
structural rearrangement that was inherited and segregated with disease 
but was not found at appreciable frequency in the Finnish control samples or in 
other published data sets (1000 Genomes, Database of Genomic Variants). 
We reviewed all loci that passed initial screening manually using IGV10.  Although 
we found evidence for a number of structural polymorphisms (as would be 
expected in any population of this size), none met the criteria expected for causal 
mutations.  Additional small-indel and structural-variation detection was 
performed using an in-house tool (unpublished). 
 
MUC1-VNTR sequencing and assembly 
 
Cloning and Sanger sequencing 
  
PCR reactions were run on 0.8% agarose gels. Bona fide full-length PCR 
products were excised, cleaned-up by QiaQuick gel-extraction kits (Qiagen) and 
TOPO-TA cloned in pCR-4-TOPO vector in TOP10 cells (Invitrogen). After 
electroporation, kanamycin-resistant transformants (typically 8 clones per gel-
purified PCR product) were analyzed by EcoRI digestion and long-range PCR 
(see above). Bona fide full-length plasmid clones, typically 2x2 clones for each 
allele in a given individual (2 independent PCR reactions, 2 clones each, typically 
8 clones per individual) were subjected to in vitro transposition with  EZ-Tn5 
<TET-1> (Epicentre). For each clone, 384 triple-resistant (50 µg/ml Ampicillin + 
50 µg/ml Kanamycin + 10 µg/ml Tetracycline) EC100 TransforMAX (Epicentre) 
transformants were robotically picked, grown up, miniprepped and sequenced 
with TET-1 PS4 and TET-1 PS5 primers (Supplementary Table 3). Sequencing 
reactions (5 µL) contained 0.75 µL 5x sequencing buffer, 0.4 µL  BigDye 
Terminator v3.1, 0.1 µL dGTP BigDye Terminator v3.0  (all ABI), 3.5% DMSO, 
1.8 pmol sequencing primer and 1.5 µL miniprepped plasmid.  Sequencing 
reactions were thermocycled as follows: initial denaturation (1 min at 96˚C) then 
40 cycles (30 s at 96˚C, 15 s at 50˚C, 4 min at 60˚C). Extension products were 
cleaned up by ethanol precipitation and run on 3730xl DNA Analyzers (ABI).  
 
Sequence assembly 
 
The exceptionally repetitive nature of the region, as well as the presence in the 
read data of both PCR errors and sequencing errors (exacerbated by the 
extreme GC content of the repeat), required a special assembly method that 
could distinguish bona fide genomic differences from errors. The method 
included three key conceptual components:  
 
(1) The ability to distinguish between base calls supported by multiple reads from 
only a single clone, and those base calls supported by multiple clones. 
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(2) Sensitive error detection in stacks of reads determined to belong to the same 
genomic region as the result of an initial, less sensitive round of error correction. 
 
(3) Allele construction by gluing reads together along long, perfect overlaps. 
Because of the repetitive sequence content, not all assemblies were complete or 
unique.  Instead, some assembly frameworks suggested multiple possible 
resolutions across areas of ambiguity, forming entire/full networks of possible 
solutions for a particular allele. 
 
The steps performed were: 
 
1. Combining transposon pairs. The two reads of a pair were merged if we could 
find an eight-base perfect overlap between them at the expected position on 
the reads. Otherwise, the two reads were used as input to the next step but 
not joined. At this stage we also trimmed off read tails having low quality 
scores and removed vector sequence. 
 
2. Error correction. We developed a special error correction algorithm to account 
for PCR errors in a clone. 
 
(a) We found all L-mers in the reads, L = 21, discarding those for which the 
quality of the middle base was below 30. We then associated a count to 
the L-mer, namely the total number of instances in the reads, minus those 
in reads from the clone having the most instances. If the L-mer had a 
reduced count of at least two, we called it good. 
(b) Now again traverse the reads, looking at all L-mers that are not good. 
Consider the three possible L-mers obtained by changing the middle base. 
Suppose that only one of these is good, and that its reduced count is at 
least five. Then we made a ‘recommendation’ that the middle base be 
changed. 
(c) Traverse the recommendations. Carry them out, except in cases where 
two are within L/2 of each other. Set the quality score of changed bases to 
zero. 
(d) Now being a second phase of error correction by aligning the reads to 
each other, using only alignments for which the sum of the two longest 
perfect match lengths was at least 500.  
(e) For a given read, edit it, using the stack of reads aligned to it. 
 
3. Joining error-corrected reads. Reads were formed into a graph by gluing them 
together along a minimum overlap of K=544. We then deleted all material in 
the graph that could not be found on a path from the first PCR primer to the 
second. Finally, we simplified the graph to reflect known limitations on the 
size of the PCR product. 
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Supplementary Figure 1.  Linkage pedigrees.  Depicted individuals are those who were (1) 
linkage-analyzed, (2) sequenced, (3) genotyped, or (4) otherwise required for pedigree 
connectivity of other included family members.  Filled symbols indicate affected individuals.  
Unfilled symbols indicate unaffected individuals.  Grey symbols indicate unknown affection 
status.  To protect patient privacy we have altered some pedigree drawings by adding or 
removing up to two unaffecteds and assigning sex randomly.  This does not matter for the 
analysis. 
1  !
Family 1!I
II  !
III  !
IV  !
1 2
1 2 3 4
1 2 3 4 5 6 7 8 9 10  !
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5 6 7 8
11  ! 12  ! 13  !
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VI  !
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II  !
III  !
IV  !
1  ! 2 3
1 2
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II  !
III  !
IV  !
1  ! 2  !
1  ! 2 ! 3  ! 4  !
1  ! 2  ! 3  ! 4  !
1  ! 2  ! 3  ! 4  ! 5  ! 6  ! 7  ! 8  ! 9  ! 10  !
1  ! 2  ! 3  ! 4  ! 5  ! 6  ! 7  !
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I  !
II  !
III  !
1  ! 2 ! 3  !
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AAGGAGACTTCGGCTACCCAGAGAAGTTCAGTGCCCAGCTCTACTGAGAAGAATGCTGTG 1 
AGTATGACCAGCAGCGTACTCTCCAGCCACAGCCCCGGTTCAGGCTCCTCCACCACTCAG 2 
GGACAGGATGTCACTCTGGCCCCGGCCACGGAACCAGCTTCAGGTTCAGCTGCCACCTGG 3 
GGACAGGATGTCACCTCGGTCCCAGTCACCAGGCCAGCCCTGGGCTCCACCACCCCGCCA 4  
GGACAGGATGTCACCTCGGTCCCAGTCACCAGGCCAGCCCTGGGCTCCACCACCCCaCCA 4’ 
GCCCACGATGTCACCTCAGCCCCGGACAACAAGCCAGCCCCGGGCTCCACCGCCCCCCCA 5 
 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCCCCCCCA X 
GCCCACGGTGTCACCTCGGCCCCGGAgAgCAGGCCGGCCCCGGGCTCCACCGCgCCCgCA A 
GCCCACGGTGTCACCTCGGCCCCGGAgAgCAGGCCGGCCCCGGGCTCCACCGCCCCCCCA B 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCCCCCCaA C 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCcGCCCCGGGCTCCACCGCCCCCCCA D 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCcGCCCCGGGCTCCACCGCgCCCgCA E 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCCCCCaCA F 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCgCCCgCA G 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCCgCCCCA H 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCgCCCCCA I 
GCCCACGGTGTCACCTCGGCaCCGGAgAgCAGGCCGGCCCCGGGCTCCACCGCgCCCgCA J 
GCCCACGGTGTCACCTCGGCCCCGGAgAgCAGGCCGGCCCtGGGCTCCACCGCCCCCCCA K 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCaCCCCCA V 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCGGGCTCCACCGCCCCCCCg W 
 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCGGGCCCCGGGCTCCACCCCGGCCCCG 6 
GCCCACGGTGTCACCTCGGCCCCGGACACCAGGCcGGCCCCGGGCTCCACCCCGGCCCCG 6’ 
GGCTCCACCGCCCCCCCAGCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGCCCCG 7 
GGCTCCACCGCCCCCCCAGCCCATGGTGTCACCTCGGCCCCGGACAACAGGCCCGCCTTG 8 
GGCTCCACCGCCCCTCCAGTCCACAATGTCACCTCGGCCTCAGGCTCTGCATCAGGCTCA 9 	  
Supplementary Figure 2. Common 60-mer units found within and near the MUC1 VNTR.  
Oriented relative to the coding strand of MUC1 (negative strand of hg19), 60-mer units 1-5 
(including variant 4’) appear near the beginning of the VNTR, whereas 6-9 (and variant 6’) 
appear near the end. The rest are in the middle, and are very similar to the ‘canonical’ unit X, 
with variant bases shown in lower case.  The underlined base in structure 9 corresponds to 
hg19 chr1 position 155,160,963, and the underlined base in structure 1 corresponds to hg19 
chr1 position 155,162,030. 	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(a) F4:IV-2 (identical to F4:V-3 assembly) 
 
1-2-3-4-5-C-X-D-E-C-F-X-X-A-B-D-E-C-X-X-X-A-A-B-X-X-X-X-X-X-G-A-B-X-X-
X-X-X-X-V-6’-7-8-9 
 
 
(b) F6:IV-3 
 
1-2-3-4’-5-C-X-D-X-A-A-A-A-B-X-X-X-X-B-A-A-B-X-X-X-X-X-X-X-G-A-B-X-X-X-
X-X-X-X-X-6-7-8-9 
 
 
(c) F2:IV-3 
 
1-2-3-4-5-C-X-D-E-C-X-H-X-A-A-B-D-E-C-X-X-X-A-A-B-X-X-X-X-X-E-C-X-X-X-
A-A-B-X-X-X-X-X-X-X-X-X-X-X-X-X-X-V-X-A-J-B-X-X-X-X-X-X-V-6’-7-8-9 
 
 
Supplementary Figure 3. Complete assemblies of risk alleles from three families.  For 
families 2, 4, and 6 the structure of the risk MUC1-VNTR allele was determined almost exactly, 
and we are thus able to determine the position of the mutant repeat unit and its sequence 
context, both of which are different in all three cases.  Each assembly is depicted as a series of 
60-mer units (Supplementary Fig. 2) covering hg19 chr1 positions 155,160,963 to 
155,162,030 (inclusive), and oriented relative to the MUC1 coding strand (hg 19 negative 
strand).  Units shown in red contain the insertion of an extra C into the C7 sequence appearing 
at positions 53-59.  For (a) and (b), the exact allele structure is shown, whereas for (c), the 
structure is completely determined except for the exact length of the stretch X-X-X-X-X-X-X-X-
X-X-X-X-X-X (14 copies, shown in blue), whose predicted length from the gel size is 13.8 
copies, and which, given limitations in gel measurement accuracy, could in fact be 13, 14 or 15 
copies. 	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(a) CEPH mother (NA12892), short allele = CEPH child short allele 
 
1-2-3-4-5-C-X-D-E-C-F-X-X-A-B-D-E-C-X-X-W-A-A-B-X-X-G-A-B-X-X-X-X-X-X-
V-6’-7-8-9 
 
(b) CEPH mother (NA12892), long allele 
 
1-2-3-4-5-C-X-D-E-C-X-H-X-A-B-D-E-C-X-X-X-A-A-B-X-X-X-X-X-X-X-X-X-I-X-
A-J-B-X-X-X-X-X-X-V-6’-7-8-9 
 
(c)	  CEPH father (NA12891), short allele 
 
1-2-3-4-5-C-X-D-E-C-F-X-X-A-B-D-E-C-X-X-X-A-A-B-X-X-X-X-X-G-A-B-X-X-X-
X-X-X-V-6’-7-8-9 
 
(d) CEPH father (NA12891), long allele = CEPH child long allele 
 
1-2-3-4-5-C-X-D-E-C-X-X-X-A-A-B-X-X-X-X-X-A-A-A-B-X-X-X-X-X-A-A-X-X-X-
X-X-X-X-X-A-A-B-X-X-X-X-B-B-X-X-A-A-B-X-X-X-B-A-A-X-X-X-X-X-X-X-V-6-7-
8-9 
 
(e) F1:IV-2 = F5:IV-5 = F6:IV-3= F6:IV-4 non-risk alleles 
 
1-2-3-4-5-C-X-D-E-C-F-X-X-A-B-D-E-C-X-X-X-A-A-B-X-X-X-X-X-X-G-A-B-X-X-
X-X-X-X-V-6’-7-8-9 
 
(f) F1:V-6 
 
1-2-3-4-5-C-X-D-E-C-X-X-X-A-A-B-X-X-X-X-X-X-G-A-B-X-X-X-X-X-X-G-A-B-X-
X-X-X-X-X-V-6-7-8-9 
 
(g) F2:IV-5 
 
1-2-3-4-5-C-X-D-E-C-X-H-X-A-A-K-D-E-C-X-X-X-A-A-A-B-X-X-X-X-V-6’-7-8-9 
 
(h) F5:IV-1 
 
1-2-3-4-5-C-X-D-E-C-X-X-X-A-A-B-X-X-X-X-X-A-A-A-B-X-X-X-X-X-A-A-X-X-X-
X-X-X-X-A-A-B-X-X-X-X-B-X-X-A-A-B-X-X-X-X-B-A-A-X-X-X-X-X-G-A-B-X-X-X-
X-X-X-V-6-7-8-9 
 
Supplementary Figure 4. Complete assemblies of non-risk alleles.  In several instances, 
the structure of the non-risk MUC1-VNTR allele was determined exactly.  Each assembly is 
depicted as a series of 60-mer units (Supplementary Fig. 2) covering hg19 chr1 positions 
155,160,963 to 155,162,030 (inclusive), and oriented relative to the MUC1 coding strand (hg 
19 negative strand). 
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Supplementary Figure 5. Ambiguous assembly of a risk allele.	  	  For individual F2:IV-3’s 
risk allele, the assembly of amplicon sequence data yielded a graph as shown, with an edge 
count of 5.  The semantics of such a graph is that the true allele should be represented by 
some path through the graph from beginning to end. There are infinitely many paths through 
this particular graph, depending on how many times each loop is traversed, however almost all 
are inconsistent with the approximate amplicon size as measured from the long-range PCR gel 
(4.1 kb).  Indeed we reasoned that the only probable paths are those that traverse the first loop 
exactly 1 time, and the second loop between 5 and 7 times. This gives the same result as the 
assembly of the risk allele as depicted in Supplementary Fig. 2 (c).	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1-2-3-4-5-C-X-D-E-C-X-H-X-A-A-B-D-E-C! X-X-X-A-A-B-X-X-X-X-X-X-X-X! V-X-A-J-B-X-X-X-X-X-X-V-6’-7-8-9!
X-X-X-A-A-B-X-X-X-X-X-E-C! X!
	   15	  
 
 
Nationality/Ethnicity MUC1 
mutation 
identified 
Renal histopathology  Age of onset of 
end-stage kidney 
disease in 
affected family 
members 
Generations 
affected 
Number of 
affected 
individuals 
sequenced 
in whom a 
mutation 
was found 
Number of 
unaffected 
individuals 
sequenced 
in whom a 
mutation 
was found 
Initial scan:  families with linkage to chromosome 1 
1 Middle Eastern Yes Focal interstitial fibrosis 29,32,33,34,37,40
,54,60,63,69 
5 10/10 0/18 
2  African American Yes Patchy, mild interstitial 
fibrosis 
43,43,45,57,60,61
,64 
4 8/8 0/10 
3  Native American Yes Tubular atrophy and 
interstitial fibrosis 
36,38,38,42,43,45
,49,56,65,67 
5 12/12 0/11 
4 European American Yes Widespread tubular 
distension and tubular 
microcystic dilatation 
45,50,50,60,65,79 4 4/4 0/5 
5 European American Yes No biopsy available 22,22,23,23,33,33 4 5/5 0/2 
6  European American Yes Marked tubular atrophy 27,31,32,40,44 6 4/4 0/7 
Mutational analysis of additional families/cases (none with linkage data except Finnish family 64) 
1 European American Yes Chronic tubulo-
interstitial fibrosis 
32 2 3/3 0/0 
2 European American Yes Patchy tubular atrophy 
and interstitial fibrosis 
75,75 5 3/3 0/0 
3 European American Yes Mild interstitial fibrosis 43,44 4 1/1 0/0 
4 European American Yes No biopsy 27,32,31,27,39 5 1/1 0/0 
5 African American Yes No biopsy 26,30,39,49 3 2/2 0/0 
6 Finnish Yes Tubulo-interstitial 
disease 
52,52,53,53 5 1/1 0/0 
7 European American Yes No biopsy 21,27,30,34,34,35
,36 
4 1/1 0/0 
8 European American Yes No biopsy 28,35 2 1/1 0/0 
9 European American Yes Severe chronic tubulo-
interstitial disease 
39 2 1/1 0/0 
10 European American Yes No biopsy  2 1/1 0/0 
11 Australian Yes No biopsy  16,23,25,28,31,31 3 3/3 0/0 
12 European Yes Tubulo-interstitial 
disease, positive 
staining for mutant 
MUC1 
 1 1/1 0/0 
13 European Yes Tubulo interstitial 
disease, positive 
staining for mutant 
MUC1 
30,44,50 3 1/1 0/0 
14 European American No No biopsy 22,55,56 2 0/1 0/0 
15 European American No Chronic tubulo-
interstitial disease 
40,40,50 2 0/1 0/0 
16 European American No Moderate patchy 
interstitial fibrosis 
37,45,55 3 0/2 0/0 
17 Canadian No No biopsy 45,54,64,65,79,85 3 0/1 0/0 
18 European American No No biopsy  1 0/1 0/0 
19 European American No No biopsy 64 2 0/1 0/0 
20 European No No biopsy  1 0/1 0/0 
21 European No No biopsy  1 0/1 0/0 
 
Supplementary Table 1.  Clinical characteristics of studied families. 
	   16	  
	  
Family ID Affected Relationship Linkage 
sharing 
across 
VNTR 
Linkage haplotypes 
across VNTR 
VNTR 
size in 
bases 
Edge 
count in 
VNTR 
assembly 
+C found 
in 
sequence 
data 
+C found 
by 
genotype 
assay 
F1-a 2,640 1 N IV-2 Y F1-b (risk) (4.8kb) 12 Y Y 
F1-c 2,700 1 N 1 V-6 Y 
aunt/ 
nephew IBD1 
F1-b (risk) (4.8kb) 50 Y Y 
F2-a 2,100 1 N IV-5 Y F2-b (risk) (4.1kb) 19 Y Y 
F2-c (2.2kb) 13 N 2 IV-3 Y 
second 
cousins IBD1 
F2-b (risk) (4.1kb) 5 Y Y 
F3-a (risk) (4.8kb) 13 Y III-13 Y F3-b (4.8kb) n/s? ? Y 
F3-c (4.0kb) 47 N 3
1 
III-16 Y 
full sibs IBD1 
F3-a (risk) (4.8kb) 39 Y Y 
F4-a (risk) 2,641 1 Y V-3 Y F4-b (4.3kb) n/a ? Y 
F4-a (risk) 2,641 1 Y 4 IV-2 Y 
first cousins 
once 
removed 
IBD1 
F4-c (4.5kb) n/a ? Y 
F5-a 2,640 1 N IV-5 Y F5-b (risk) (4.7kb) 33 Y Y 
F5-c 4,680 1 N 5
2 
IV-1 Y 
half first 
cousins IBD1 
F5-b (presumed risk) (4.7kb) n/s? ? Y 
F6-a 2,640 1 N IV-3 Y F6-b (presumed risk) 2,641 1 Y Y 
F6-c 2,640 1 N 6
3 
IV-4 N 
first cousins IBD0 
F6-d (4.6kb) 12 N N 
CEPH-a 2,400 1 N mom N CEPH-b 2,940 1 N N 
CEPH-c 2,580 1 N dad N CEPH-d 4,320 1 N N 
CEPH-a 2,400 1 N 
CEPH 
child N 
 
CEPH-d 4,320 1 N N 
 
 
Supplementary Table 2.  Summary of MUC1-VNTR assemblies.	  	  Knowledge of IBD sharing 
between/among sequenced individuals and the segregation of different phased SNP-marker 
haplotypes across the VNTR region were used to assign the sequenced MUC1 alleles to the 
different observed categorical linkage haplotypes, where possible.  Furthermore, where able, 
we have assigned VNTR alleles to a pedigree’s risk haplotype.  The reported size of each 
allele’s assembly covers hg19 chr1 155,160,963 to 155,162,030 (inclusive).  Numbers in 
parentheses are estimated sizes derived from long-range PCR gels in those cases where the 
allele was not assembled or did not assemble into a single unambiguous solution with an edge 
count of 1.  Alleles with edge counts of “n/a” were not assembled, and alleles with edge counts 
of “n/s?” are believed to have not been assembled due to inadequate separation from the 
individual’s other allele prior to molecular cloning. 	  
	   17	  
	  
Name Method Comment Primer sequence 
PS1 MUC1-VNTR 
Southern blot 
biotinylated /52-Bio/ 
CAGCCCACGGTGTCACCTCGGCCCCGGACACCAGGCCGGC
CCCGGGC /iBiodT/ 
CCACCGCCCCCCCAGCCCACGGTGTCACC /iBiodT/ 
CGGCCCCGGACACCAGGCCGGC 
PS2 MUC1-VNTR 
long-range 
PCR 
forward GGAGAAAAGGAGACTTCGGCTACCCAG 
PS3  reverse GCCGTTGTGCACCAGAGTAGAAGCTGA 
PS4 Sanger 
sequencing 
of clones 
forward GGGTGCGCATGATCCTCTAGAGT 
PS5  reverse TAAATTGCACTGAAATCTAGAAATA 
PS6 C-insertion 
genotype 
assay 
forward CTGGGAATCGCACCAGCGTGTGGCCCCGGGCTCCACC 
PS7  reverse CGTGGATGAGGAGCCGCAGTGTCCGGGGCCGAGGTGACA 
PS8  extension CGGGCTCCACCGCCCCCCC 	  
Supplementary Table 3.  Primer sequences.	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